tbuckley/cabot-search huggingface dataset:
Update of AMC 0101 study: A phase III trial of intraperitoneal cisplatin and early mitomycin-C plus long-term doxifluridine plus cisplatin (iceMFP) versus mitomycin-C plus short-term doxifluridine (Mf) as adjuvant chemotherapy for grossly serosa-positive advanced gastric cancer (NCT00296322).
Authors: Yoon-Koo Kang, Baek-Yeol Ryoo, Heung-Moon Chang, Dae Young Zang, Tae Won Kim, Dae Hyun Yang, Se Jin Jang, Jeong Hwan Yook, Sung Tae Oh, Byung Sik Kim
Journal: Journal of Clinical Oncology (2012)

4 Background: To improve the adjuvant chemotherapy in serosa-involving AGC, we adopted intraperitoneal and early start of chemotherapy, as well as prolongation of fluoropyrimidine and addition of cisplatin (P) to Mf regimen. The primary efficacy results of AMC0101 study on 3y relapse free survival rate (RFSR) were presented in 2008 ASCO. Now, we update the results with longer follow up. Methods: Pts with serosa-positive AGC who underwent curative resection were randomized to receive either Mf or iceMFP. Pts with postoperative stage I or IV (M1) were excluded. For Mf, 20 mg/m 2 of mitomycin-C (M) was injected 3-6 wks after surgery and 4 wks later, 460-600 mg/m 2 /day of doxifluridine was administered orally for 3 months. For iceMFP, 100 mg of P was administered intraperitoneally for 2 h during surgery and 15 mg/m 2 of M was injected 1 day after surgery. Doxifluridine was started 4 wks after surgery and extended for a total of 12 months and 6 shots of monthly 60 mg/m 2 of P were added. Results: Between Oct 2001 and Apr 2007, 640 pts were randomized (318 in Mf, 322 in iceMFP). One hundred and nineteen pts (60 in Mf, 59 in iceMFP) were excluded (postoperative stage I in 90, M1 in 13, positive resection margin in 10, and others in 6). Therefore, a total of 521 pts (258 in Mf, 263 in iceMFP) were eligible for intent-to-treat analysis. Postoperative stages were II in 33.4%, IIIA in 31.9%, IIIB in 17.5%, and IV in 17.3% of pts. As of April 2011, with a median follow-up of 6.6 years, iceMFP group had a significantly longer RFS (HR, 0.73; 95% C.I. 0.57 - 0.93; p=0.0092) and overall survival (HR, 0.77; 95% C.I. 0.60 - 0.98; p=0.0365) than Mf group. Conclusions: We could confirm with longer follow up that benefit in 3y RFSR from iceMFP could be translated into benefit in 5y OSR. Considering no benefit of adding cisplatin and prolongation of doxifluridine to Mf chemotherapy in curatively resected AGC pts (AMC 0201), intraperitoneal cisplatin and/or early start of chemotherapy seemed to be responsible for the improved efficacy of iceMFP chemotherapy in this study.
Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) Is Accompanied by Endotoxemia, Activation of Endotoxin-Directed Innate Immunity, and Deficiency of Endogenous Proteins That Limit Endotoxin- Induced TNF Production
Authors: Ofer Levy, Eugenie E. Suter, Leslie A. Kalish, Leighanne C. Gallington, Athmane Teghanemt, Suganya Viriyakosol, Robert J. Soiffer, Jerrold Weiss, Patrick Scannon, Hoi M. Leung, Gregory Priebe, Janice Russell, Paul Walker, Michael R. Wessels, Eva Guinan
Journal: Blood (2008)
The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study
Authors: Mallika Imwong, Kanokon Suwannasin, Chanon Kunasol, Kreepol Sutawong, Mayfong Mayxay, Huy Rekol, Frank M Smithuis, Tin Maung Hlaing, Kyaw M Tun, Rob W van der Pluijm, Rupam Tripura, Olivo Miotto, Didier Menard, Mehul Dhorda, Nicholas P J Day, Nicholas J White, Arjen M Dondorp
Journal: The Lancet Infectious Diseases (2017)

BackgroundEvidence suggests that the PfKelch13 mutations that confer artemisinin resistance in falciparum malaria have multiple independent origins across the Greater Mekong subregion, which has motivated a regional malaria elimination agenda. We aimed to use molecular genotyping to assess antimalarial drug resistance selection and spread in the Greater Mekong subregion.MethodsIn this observational study, we tested Plasmodium falciparum isolates from Myanmar, northeastern Thailand, southern Laos, and western Cambodia for PfKelch13 mutations and for Pfplasmepsin2 gene amplification (indicating piperaquine resistance). We collected blood spots from patients with microscopy or rapid test confirmed uncomplicated falciparum malaria. We used microsatellite genotyping to assess genetic relatedness.FindingsAs part of studies on the epidemiology of artemisinin-resistant malaria between Jan 1, 2008, and Dec 31, 2015, we collected 434 isolates. In 2014–15, a single long PfKelch13 C580Y haplotype (−50 to +31·5 kb) lineage, which emerged in western Cambodia in 2008, was detected in 65 of 88 isolates from northeastern Thailand, 86 of 111 isolates from southern Laos, and 14 of 14 isolates from western Cambodia, signifying a hard transnational selective sweep. Pfplasmepsin2 amplification occurred only within this lineage, and by 2015 these closely related parasites were found in ten of the 14 isolates from Cambodia and 15 of 15 isolates from northeastern Thailand. C580Y mutated parasites from Myanmar had a different genetic origin.InterpretationOur results suggest that the dominant artemisinin-resistant P falciparum C580Y lineage probably arose in western Cambodia and then spread to Thailand and Laos, outcompeting other parasites and acquiring piperaquine resistance. The emergence and spread of fit artemisinin-resistant P falciparum parasite lineages, which then acquire partner drug resistance across the Greater Mekong subregion, threatens regional malaria control and elimination goals. Elimination of falciparum malaria from this region should be accelerated while available antimalarial drugs still remain effective.FundingThe Wellcome Trust and the Bill and Melinda Gates Foundation.
The Baseline PET SUV Correlates Better with Clinical Outcome Than the Post-Therapy PET Scan in Previously Untreated Patients with Histologically Aggressive Non-Hodgkin Lymphoma (NHL)
Authors: Fernando Cabanillas, Jorge Toro, Jorge Perdomo, Orestes Pavia, Idalia Liboy, Clara Salgado, Viviana Freire, Ezequiel Rivera, Norman Maldonado
Journal: Blood (2008)
A New Prognostic Index for Multiple Myeloma Patients in the Era of Novel Agents
Authors: Hyungwoo Cho, Cheolwon Suh, Dok Hyun Yoon, Ji Hyun Park, Shin Kim, Sang-wook Lee, Chan-Sik Park, Jooryung Huh, Kyoungmin Lee, Eun Hee Kang, Jung Sun Park, Chan-Jeoung Park, Jin Seok Kim, Kihyun Kim
Journal: Blood (2014)
A first-in-human phase I study of MORAb-004 (MOR4), a humanized monoclonal antibody recognizing TEM-1 (endosialin), in patients with solid tumors.
Authors: R. D. Carvajal, M. M. Gounder, C. M. Coughlin, J. Fishel, J. Heyburn, D. O'Shannessy, L. Grasso, C. Schweizer, J. Parno, L. J. Old, N. S. Azad, L. A. Diaz
Journal: Journal of Clinical Oncology (2011)

3086 Background: TEM-1 is a novel anticancer target expressed in many human malignancies and critical to tumor development. It is a transmembrane glycoprotein found on the cell surface of activated mesenchymal cells (e.g. pericytes, fibroblasts and mesenchymal tumor cells) and is involved in the development of tumor vasculature, stromal/tumor organization and PDGFb receptor signaling. MOR4 is a humanized IgG monoclonal antibody and is the first agent to target TEM-1. It has antitumor activity in a variety of models. Methods: Given the role of TEM-1 in tumorigenesis, a phase I dose escalation study in patients (pts) with advanced solid tumors was conducted to evaluate the safety, pharmacokinetic profile and preliminary efficacy of MOR4 administered intravenously on a weekly schedule. Results: 23 pts refractory to standard therapy were treated at 8 dose levels (0.0625 to 8 mg/kg). No DLT has been observed; however, an adverse event (AE) of tumor bleeding occurred at 0.5mg/kg in a pt with uterine sarcoma. Other frequent drug-related AEs included grade 1-2 fatigue, fever, chills, myalgia and headache. Preliminary pharmacokinetic (PK) data demonstrate MOR4 accumulation upon weekly dosing and that elimination mechanisms are saturable beginning at 0.25 mg/kg. Exposure (AUC) increases in a greater than dose-proportional manner, with the apparent t1/2 increasing proportionally with dose. Median progression-free survival to date is 18.1 weeks (95% CI, 7.6-47.1 weeks), with 3 pts achieving minor responses (mesothelioma, pancreatic neuroendocrine tumor (PNET) and sarcoma) and 5 others achieving durable stable disease >8 weeks (range, 15-47 weeks; sarcoma, hepatocellular, small bowel and colorectal carcinoma [n=2]). Analysis of archival tumor (n=7) revealed TEM-1 stromal and CD34+ vessel staining in all cases, with TEM-1 tumor cell expression observed in 4/7 cases. Conclusions: MOR4 is well tolerated with clinical efficacy observed in pretreated pts. Expanded cohorts at 1, 2 and 4 mg/kg are ongoing to define an efficacious and optimal biologic dose using paired tumor biopsies and DCE-MRI.
SDF-1-CXCR4 and HGF-c-met Axes Regulate Mobilization/Recruitment to Injured Tissue of Human Mesenchymal Stem Cells.
Authors: Bo-Ra Son, Dongling Zhao, Leah A. Marquez-Curtis, Neeta Shirvaikar, Mariusz Z. Ratajczak, Anna Janowska-Wieczorek
Journal: Blood (2004)
Patient outcome measures during prolonged survival in patients (Pts) with high-risk myelodysplastic syndromes (MDS) treated with azacitidine (AZA)
Authors: V. Santini, P. Fenaux, G. J. Mufti, E. Hellström-Lindberg, A. F. List, L. R. Silverman, J. F. Seymour, J. Backstrom, D. McKenzie, C. L. Beach
Journal: Journal of Clinical Oncology (2008)

7028 Background: A recent phase III trial showed AZA is the first treatment to significantly extend overall survival (OS) in higher- risk MDS pts (Fenaux, Blood 2007;110:817). This subsequent analysis explored improvements in patient outcomes during prolonged survival, as reflected by transfusion requirements, cytopenias, levels of anemia, infections requiring antimicrobial agents, and hospitalization days. Methods: 358 pts with higher-risk MDS, defined as FAB RAEB, RAEB-T, or CMML and IPSS Int-2 or High, were enrolled. Pts were randomized to AZA (75 mg/m2/d SC x 7d q 28d) + best supportive care (BSC) or conventional care regimens (CCR). CCR + BSC included low-dose ara-C (20 mg/m2/d x 14d q 28d), or standard chemotherapy (7+3 regimen), or BSC only. Prophylactic G-CSF and erythropoietin were not allowed. Results: Significantly more RBC transfusion-dependent pts at baseline (BL) achieved transfusion independence (TI) with AZA vs CCR and significantly more pts who were RBC TI at BL remained TI with AZA vs CCR (Table). Similarly, significantly more pts treated with AZA vs CCR had any IWG 2000 hematologic improvement (49% vs 29%, p<0.0001). The hazard ratio for anemia with AZA vs CCR was 0.89 (95%CI: 0.82, 0.97; p=0.009). Rate of infection requiring IV antimicrobial treatment was reduced by one- third with AZA vs CCR (relative risk [RR] = 0.67; 95%CI: 0.35, 1.20; p=0.133). Risk of additional days in the hospital was significantly reduced with AZA vs CCR (RR = 0.82; 95%CI: 0.81, 0.88; p<0.0001). On average, AZA pts had approximately 7 fewer days per pt-year in the hospital. Conclusions: In addition to prolonging OS, AZA was associated with improved patient outcome measures demonstrated by clinically meaningful reductions in transfusion requirements, cytopenias, anemia, infections requiring antimicrobial agents, and hospitalization days. Further research is needed to measure the impact of these improvements on overall quality of life and health economic measures for these pts. RBC Transfusion Independence After Therapy RBC AZA n/N, % [95%CI] CCR n/N, % [95%CI] Difference AZA vs CCR P value BL-Dependent 50/111, 45% [36, 55] 13/144, 11% [6, 19] 34% <0.0001 BL-Independent 58/68, 85% [75, 93] 37/65, 57% [44, 69] 28% 0.0005 Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Pharmion Amgen, Celgene, EMB Statistical Solutions, LLC, Pharmion Pharmion Amgen, Celgene, Cephalon, Johnson & Johnson, Novartis, Pharmion, Roche Pharmion
Attention alters predictive processing
Authors: Andy Clark
Journal: Behavioral and Brain Sciences (2016)

Firestone & Scholl (F&S) bracket many attentional effects as "peripheral," altering the inputs to a cognitive process without altering the processing itself. By way of contrast, I highlight an emerging class of neurocomputational models that imply profound, pervasive, nonperipheral influences of attention on perception. This transforms the landscape for empirical debates concerning possible top-down effects on perception.
The Expression of the ER Stress Sensor GRP78/Bip Is a Target of R-CHOP and Bortezomib Treatments in DLBCL with Prognostic Value. A Rationale for the Use of Proteasome Inhibitors in DLBCL Patients.
Authors: Ana Mozos, Gael Roue, Armando López-Guillermo, Pedro Jares, Dolors Colomer, Elias Campo, Antonio Martinez
Journal: Blood (2009)
Cytogenetics Abnormalities Predict the Outcome of Allogeneic Transplantation In AML: A CIBMTR Study
Authors: Philippe Armand, Waleska Perez, Mei-Jie Zhang, Haesook Kim, Thomas R. Klumpp, Paola Dal Cin, Edmund K Waller, Mark R. Litzow, Jane L. Liesveld, Hillard M. Lazarus, Andrew Artz, Vikas Gupta, Bipin N. Savani, Philip L. McCarthy, Jean-Yves Cahn, Harry Schouten, Jurgen Finke, Edward D. Ball, Mahmoud Aljurf, Corey Cutler, Jacob M. Rowe, Joseph H. Antin, Luis M Isola, Paolo Di Bartolomeo, Bruce Camitta, Alan M Miller, Mitchell S. Cairo, Keith E. Stockerl-Goldstein, Jorge Sierra, Mary Lynn Savoie, Joerg Halter, Patrick J Stiff, Chadi Nabhan, Ann A. Jakubowski, Donald Bunjes, Effie W. Petersdorf, Steven M Devine, Richard Maziarz, Martin Bornhauser, Victor A Lewis, David I. Marks, Christopher N Bredeson, Robert Soiffer, Daniel J. Weisdorf
Journal: Blood (2010)
For better or worse, or for a change?
Authors: Sebastien Bouret
Journal: Behavioral and Brain Sciences (2016)

Abstract The noradrenergic system is intimately related to the autonomic system and is thought to play a key role at the interface between arousal and cognition. The GANE (glutamate amplifies noradrenergic effects) theory proposes a complete account of that role, with an emphasis on the quantitative effect of noradrenaline on stimulus processing. This is in marked contrast to network reset theory, which emphasizes the qualitative effect of noradrenaline of updating the representation of the environment.
Quality of Life Results From Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Indolent Non-Hodgkin's Lymphoma
Authors: Lynne I. Wagner, Fengmin Zhao, Michael E. Williams, Randy D. Gascoyne, John C. Krauss, David Cella, Sandra J. Horning, Brad S. Kahl
Journal: Blood (2012)
The pro- or antiarrhythmic actions of polyunsaturated fatty acids and of cholesterol
Authors: R. Coronel
Journal: Pharmacology & Therapeutics (2017)

In this review, the pro- and anti-arrhythmic effects of a diet rich in fish oil fatty acids and of hypercholesterolemia will be discussed in relation to two major mechanisms of arrhythmogenesis (triggered activity and re-entry). Whereas a diet rich in fish oil is pro-arrhythmic in relation to re-entry based arrhythmias (as occur in acute myocardial ischemia) and anti-arrhythmic in relation to triggered activity based arrhythmias (as occur in heart failure), the reverse is true for hypercholesterolemia. Changing the lipid composition of cardiomyocytes likely has powerful pro- or anti-arrhythmic consequences, depending on the mechanism of arrhythmias, and has corresponding therapeutic potential.
Influence of Glutathione S-Transferase (GST) Gene Polymorphisms On the Clearance of Intravenous Busulfan in Adult Patients Undergoing Hematopoietic Cell Transplantation.
Authors: Sung-Doo Kim, Je-Hwan Lee, Seong-Gil Ryu, Eun-Hye Hur, Mun Jung Kang, Jung-Hee Lee, Dae-Young Kim, Sung-Nam Lim, Young-Shin Lee, Young-Ah Kang, Hyeong-Seok Lim, Kyun Seop Bae, Gyu Jeong Noh, Sung-Cheol Yun, Sang Beom Han, Kyoo-Hyung Lee
Journal: Blood (2009)
Continuity of primary care matters and should be protected
Authors: Peter Tammes, Chris Salisbury
Journal: BMJ (2017)

Continuity could be a key line of defence against rising hospital admissions

Healthcare systems in many countries are seeking to reduce hospital admissions for patients with conditions manageable in primary care, so called ambulatory care sensitive conditions. One approach has been to seek to improve access to primary care, but this might have the unintended effect of reducing continuity of care.1

Continuity of care is an important aspect of primary care that is highly valued by patients and general practitioners and is associated with a range of improved patient outcomes.23 Recent policy in the UK has sought to achieve a balance between access and continuity by introducing a named accountable GP for each patient. This policy was first introduced for patients aged 75 and over, to provide personalised care to keep older people healthy and out of hospital.45 Therefore, the study by Barker and colleagues (doi:10.1136/bmj.j84), which examines the association between continuity of primary care and admissions for ambulatory care sensitive conditions …
Phase II study of paclitaxel and cisplatin for metastatic or recurrent esophageal cancer
Authors: S.-H. Cho, I.-J. Chung, D.-H. Yang, J.-R. Byun, Y.-K. Kim, J.-J. Lee, H.-J. Kim
Journal: Journal of Clinical Oncology (2005)

4076 Background: Paclitaxel, an agent with broad antitumor activity, is one of the most active agents against esophageal cancer. Reduced tolerance to toxic chemotherapy is main problem in patients with metastatic or recurrent esophageal cancer resulted from larger tumor burden, older ages, and comorbidities. In this study, we performed a phase II study to assess the activity of the paclitaxel and cisplatin in metastatic or recurrent esophageal cancer. Methods and Patients: From April 1999 and June 2003, 32 patients with metastatic or unresectable esophageal cancer recurring after previous treatments were enrolled into this study. All patients had ECOG PS 0–2, adequate bone marrow and renal function, total bilirubin < 2mg/dl. Patients received biweekly paclitaxel (90 mg/m2 in a 3-h infusion) followed by cisplatin (50 mg/m2), and were re-evaluated after every three cycles of chemotherapy. Results: 32 patients have been enrolled with the following characteristics: median age 60 years, M/F 32/0, PS 0/1/2: 9/18/5. A total of 151 cycle gave been given (median 5.1 cycles/patient). Grade 3–4 toxicity included: neutropenia: 4 patients (13%), thrombocytopenia/anemia: 1 patients, respectively (3%), asthenia: 7 patients (22%), nausea/vomiting: 3 patients (9%), neuropathy: 0. One patient (3%) responded completely, and 12 patients (38%) showed a partial response; in 9 patients (28%) the disease remained stable, and in 10 patients (31%) it progressed. The objective response rate was 41%; greater responses were seen in the chemotherapy- or radiotherapy-naïve patients than in the other patients (P=0.049) The median duration of response was 4.8 months, and the median overall survival in all patients was 7 months (95% CI, 5.13–8.87). The 1-year and 2-year survival rates were 28.1% and 7.1%, respectively. Conclusion: Biweekly combination chemotherapy with paclitaxel and cisplatin seems to be an active regimen in metastatic or recurrent esophageal carcinoma with acceptable toxicities. No significant financial relationships to disclose.
T Cell Mediated Autologous Cytotoxicity Against Hematopoietic Precursor Cells in Low and Intermediate-1 Risk Myelodysplastic Syndrome.
Authors: Martine E.D. Chamuleau, Theresia M. Westers Ing, Linda van Dreunen, Judith Groenland, Adri Zevenbergen Ing, Corien Eeltink, Gert J. Ossenkoppele, Arjan A. Van de Loosdrecht
Journal: Blood (2007)
GANEing on emotion and emotion regulation
Authors: Thomas D Hull
Journal: Behavioral and Brain Sciences (2016)

Abstract The function of emotion and its underlying neural mechanisms are often left underspecified. I extend the GANE (glutamate amplifies noradrenergic effects) model by examining its success in accounting for findings in emotion regulation. I also identify points of alignment with construction models of emotion and with the hypothesis that emotion states function to push neural activity toward rapid and efficient action.
A Clinically Usable Gene Expression Report for Risk Assessment and Identification of Possible Therapeutic Targets in Multiple Myeloma.
Authors: Tobias Meiβner, Anja Seckinger, Thomas Hielscher, Thierry Rème, Jerome Moreaux, Axel Benner, Uta Bertsch, Anna Jauch, Kai Neben, Thomas Möhler, Bernard Klein, Hartmut Goldschmidt, Dirk Hose
Journal: Blood (2009)
Identification of a genetically defined ultra-high-risk group in relapsed pediatric T-lymphoblastic leukemia
Authors: P Richter-Pechańska, J B Kunz, J Hof, M Zimmermann, T Rausch, O R Bandapalli, E Orlova, G Scapinello, J C Sagi, M Stanulla, M Schrappe, G Cario, R Kirschner-Schwabe, C Eckert, V Benes, J O Korbel, M U Muckenthaler, A E Kulozik
Journal: Blood Cancer Journal (2017)

Abstract In the search for genes that define critical steps of relapse in pediatric T-cell acute lymphoblastic leukemia (T-ALL) and can serve as prognostic markers, we performed targeted sequencing of 313 leukemia-related genes in 214 patients: 67 samples collected at the time of relapse and 147 at initial diagnosis. As relapse-specific genetic events, we identified activating mutations in NT5C2 ( P =0.0001, Fisher’s exact test), inactivation of TP53 ( P =0.0007, Fisher’s exact test) and duplication of chr17:q11.2-24.3 ( P =0.0068, Fisher’s exact test) in 32/67 of T-ALL relapse samples. Alterations of TP53 were frequently homozygous events, which significantly correlated with higher rates of copy number alterations in other genes compared with wild-type TP53 ( P =0.0004, Mann–Whitney’s test). We subsequently focused on mutations with prognostic impact and identified genes governing DNA integrity ( TP53 , n =8; USP7 , n =4; MSH6 , n =4), having key roles in the RAS signaling pathway ( KRAS , NRAS , n =8), as well as IL7R ( n =4) and CNOT3 ( n =4) to be exclusively mutated in fatal relapses. These markers recognize 24/49 patients with a second event. In 17 of these patients with mostly refractory relapse and dire need for efficient treatment, we identified candidate targets for personalized therapy with p53 reactivating compounds, MEK inhibitors or JAK/STAT-inhibitors that may be incorporated in future treatment strategies.
Disease Patterns for Patients (pts) with Chronic Myeloid Leukemia (CML) That Have BCR-ABL Transcript Levels &gt; 10% At 3 Month of Therapy with Tyrosine Kinase Inhibitors (TKIs)
Authors: Aziz Nazha, Hagop M. Kantarjian, Preetesh Jain, Elias J. Jabbour, Alfonso Quintás-Cardama, Rajyalakshmi Luthra, Lynne V. Abruzzo, Gautam Borthakur, Farhad Ravandi, Sherry A. Pierce, Susan O'Brien, Jorge E. Cortes
Journal: Blood (2012)
Whole-Genome DNA Methylation Analysis of Mantle Cell Lymphoma: Biological and Clinical Implications
Authors: Ana C. Queirós, Renée Beekman, Sílvia Beà, Alba Navarro, Angelika Merkel, Simon Heath, Giancarlo Castellano, Anke Bergmann, Inga Vater, Wolfram Klapper, Christiane Pott, Ivo G. Gut, Reiner Siebert, Elias Campo, José I. Martín-Subero
Journal: Blood (2014)
A High Sensitivity Detection Technique Reveals JAK2-V617F Mutation in Additional 20% of Patients with Essential Thrombocytemia, but Not in Patients with Primary Myelofibrosis, Considered Negative with a Conventional ASO-PCR
Authors: Francesca Bertolotti, Sarah Pozzi, Massimo Ulivi, Marina Podestà, Davide Imperiale, Vittorio Rosti, Francesco Frassoni
Journal: Blood (2008)
Prévalence des tumeurs colorectales lors des coloscopies réalisées à l'hôpital général en France
Authors: A Pariente, B Nalet, V Cottet, C Milan, M Fardeheb, J Lafon, S Olschwang, C Bonati-Pellip, C Bonithon-Kopp
Journal: Endoscopy (2006)

Le rendement diagnostique de la coloscopie en matière de tumeurs colorectales est mal connu en pratique quotidienne. Nous avons déterminé la prévalence des adénomes et des cancers colorectaux en fonction de l'âge, du sexe, de l'indication de l'examen, et comparé leur fréquence chez les malades examinés pour dépistage, surveillance, ou symptômes.